Asciminib Roll-over Study

Clinical trial NCT04877522 · RECRUITING

Trial details

NCT number: NCT04877522
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Start date: 2022-08-30
Primary completion: 2030-08-30
Enrollment: 347

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.